Sunesis Pharmaceuticals to Host Conference Call on March 8th to Discuss Fourth Quarter and Full-Year 2017 Financial Results a...
March 01 2018 - 7:00AM
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it
will host a conference call on Thursday, March 8th, 2018 at 1:30
p.m. Pacific Time to discuss corporate updates and financial
results for the fourth quarter and year ended December 31, 2017.
The call can be accessed by dialing (844) 269-7720 (U.S. and
Canada) or (574) 990-1148 (international), and entering passcode
8182338.
To access the live audio webcast, or the subsequent archived
recording, visit the "Investors and Media - Calendar of Events"
section of the Sunesis website at http://ir.sunesis.com. The
webcast will be recorded and available for replay on the company's
website for two weeks.
About Sunesis
Pharmaceuticals
Sunesis is a biopharmaceutical company
developing new oncology therapeutics for the treatment of solid and
hematologic cancers. Sunesis has built an experienced cancer drug
development organization committed to improving the lives of people
with cancer. The Company is focused on advancing its novel
kinase-inhibitor pipeline, with an emphasis on establishing proof
of concept that its oral non-covalent BTK-inhibitor vecabrutinib is
effective in ibrutinib-resistant chronic lymphocytic leukemia.
Vecabrutinib is currently being evaluated in a Phase 1b/2,
open-label, sequential-group, dose-escalation and cohort-expansion
study in adults with chronic lymphocytic leukemia and other B-cell
malignancies who have progressed after prior therapies. Beyond the
development of vecabrutinib, the Company has two other kinase
inhibitor programs, including the Takeda-partnered pan-RAF
inhibitor TAK-580, which is in solid tumor trials, and Sunesis’
proprietary preclinical PDK1 inhibitor SNS-510, which is in
preclinical development with an IND submission planned in 2019.
PDK1 is a master kinase that activates other kinases
important to cell growth and survival including members of the AKT,
PKC, RSK and SGK families.
For additional information on Sunesis, please
visit www.sunesis.com.
SUNESIS and the logos are trademarks
of Sunesis Pharmaceuticals, Inc.
|
|
Investor and Media
Inquiries:Maeve ConneightonArgot Partners212-600-1902 |
Willie
QuinnSunesis Pharmaceuticals Inc.650-266-3716 |
|
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jul 2023 to Jul 2024